Results 51 to 60 of about 352,767 (265)

Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer

Frontiers in Cell and Developmental Biology, 2021
Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases.
Xinping Zhu, Masahisa Kudo, Xiangjie Huang, Hehuan Sui, Haishan Tian, Carlo M. Croce, Ri Cui, Ri Cui   +7 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine

Molecular Therapy: Nucleic Acids, 2017
Pediatric cancers differ from adult tumors, especially by their very low mutational rate. Therefore, their etiology could be explained in part by other oncogenic mechanisms such as chromosomal rearrangements, supporting the possible implication of fusion
Célia Dupain, Anne Catherine Harttrampf, Giorgia Urbinati, Birgit Geoerger, Liliane Massaad-Massade   +4 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Management of malignant inferior vena cava syndrome (IVCS) by endovascular bridging stent placement

Radiology Case Reports
A 73-year-old male patient was admitted to the emergency department with dyspnea and severe edema in the lower extremities. The patient had been diagnosed with extensive small-cell lung cancer 15 months previously.
Manos Siderakis, MD, BSc, MSc, Georgia Papavasileiou, MD, MSc, Margarita Moutou, MD, MSc, George Gkeneralis, MD, MSc, PhD, Viktoria Kartsouni, MD, MSc, PhD, Myrsini Gkeli, MD, MSc   +5 more
doaj   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Histologically Malignant Solitary Fibrous Tumour of the Anterior Thoracic Wall: A Case Report and Review of the Literature

Case Reports in Medicine, 2010
Solitary fibrous tumour (SFT) is a rare oncological entity that most often arises in the pleura. Over the past 10 years, the tumour has been described at numerous extrapleural locations.
Maria Archontaki, Dimitris P. Korkolis, Niki Arnogiannaki, Stelios Hatzijiannis, Panagiotis Dendrinos, Christos Megapanos, Dimitris Kassotakis, Georgios Kokkalis   +7 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Frontiers in Immunology, 2018
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors (ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine immunotherapies with conventional agents such as cytotoxic ...
Chloé Grasselly, Chloé Grasselly, Morgane Denis, Morgane Denis, Aurore Bourguignon, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera, Charles Dumontet, Charles Dumontet   +13 more
doaj   +1 more source

Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression

Frontiers in Cell and Developmental Biology, 2020
Fibroblast growth factor (FGF) receptor 4 (FGFR4) belongs to a family of tyrosine kinase receptor. FGFR4 is highly activated in certain types of cancer and its activation is closely associated with its specific ligand, FGF19.
Yanan Liu, Meng Cao, Yuepiao Cai, Xiaokun Li, Chengguang Zhao, Chengguang Zhao, Chengguang Zhao, Ri Cui, Ri Cui, Ri Cui   +9 more
doaj   +1 more source